261 related articles for article (PubMed ID: 37301433)
21. Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain.
Mareque M; Climente M; Martinez-Moragon E; Padilla A; Oyagüez I; Touron C; Torres C; Martinez A
J Asthma; 2023 Jun; 60(6):1210-1220. PubMed ID: 36322679
[TBL] [Abstract][Full Text] [Related]
22. Asthma Management in Adults.
Busse WW; Castro M; Casale TB
J Allergy Clin Immunol Pract; 2023 Jan; 11(1):21-33. PubMed ID: 36283607
[TBL] [Abstract][Full Text] [Related]
23. Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response.
Abbas F; Georas S; Cai X; Khurana S
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):655-660.e1. PubMed ID: 34481992
[TBL] [Abstract][Full Text] [Related]
24. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
Casale TB; Chipps BE; Rosén K; Trzaskoma B; Haselkorn T; Omachi TA; Greenberg S; Hanania NA
Allergy; 2018 Feb; 73(2):490-497. PubMed ID: 28859263
[TBL] [Abstract][Full Text] [Related]
25. Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience.
Portacci A; Iorillo I; Quaranta VN; Maselli L; Lulaj E; Buonamico E; Dragonieri S; Carpagnano GE
Respir Med; 2023 Oct; 217():107348. PubMed ID: 37422023
[TBL] [Abstract][Full Text] [Related]
26. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
Akenroye AT; Heyward J; Keet C; Alexander GC
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
[TBL] [Abstract][Full Text] [Related]
27. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
[TBL] [Abstract][Full Text] [Related]
28. Clinical effects and immune modulation of biologics in asthma.
Harada N; Ito J; Takahashi K
Respir Investig; 2021 Jul; 59(4):389-396. PubMed ID: 33893067
[TBL] [Abstract][Full Text] [Related]
29. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy.
Breslavsky A; Al Qaied A; Tsenter P; Mukaseev N; Alamor M; Cohen-Hagai K; Wand O
Respir Med; 2024 Feb; 222():107528. PubMed ID: 38199287
[TBL] [Abstract][Full Text] [Related]
31. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
32. Real-world super-response to biologics in severe asthma: A French monocentric retrospective cohort study.
Valéry S; Habib-Maillard S; Roche N
Respir Med Res; 2023 Nov; 84():101055. PubMed ID: 37897876
[TBL] [Abstract][Full Text] [Related]
33. Real-World Effectiveness of IL-5/5Ra Targeted Biologics in Severe Eosinophilic Asthma With Comorbid Bronchiectasis.
Bendien SA; Kroes JA; van Hal LHG; Braunstahl GJ; Broeders MEAC; Oud KTM; Patberg KW; Smeenk FWJM; van Veen IHPAA; Weersink EJM; Fieten KB; Hashimoto S; van Veen A; Sont JK; van Huisstede A; van de Ven MJT; Langeveld B; Maitland-van der Zee AH; Ten Brinke A;
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2724-2731.e2. PubMed ID: 37295671
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
[TBL] [Abstract][Full Text] [Related]
35. [Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS)].
Milger K; Korn S; Feder C; Fuge J; Mühle A; Schütte W; Skowasch D; Timmermann H; Suhling H
Pneumologie; 2023 Apr; 77(4):220-232. PubMed ID: 36796422
[TBL] [Abstract][Full Text] [Related]
36. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
[TBL] [Abstract][Full Text] [Related]
37. [Biologics for the treatment of severe asthma: Current status report 2023].
Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
[TBL] [Abstract][Full Text] [Related]
38. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways.
Cataldo D; Louis R; Michils A; Peché R; Pilette C; Schleich F; Ninane V; Hanon S
J Asthma; 2021 Apr; 58(4):448-458. PubMed ID: 31928102
[TBL] [Abstract][Full Text] [Related]
39. Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study.
Monzio Compagnoni M; Conflitti C; Capuano V; Bonaiti G; Franchi M; Vimercati C; Biondi A; Luppi F; Corrao G; Faverio P
Pediatr Pulmonol; 2024 Feb; 59(2):408-416. PubMed ID: 37991180
[TBL] [Abstract][Full Text] [Related]
40. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
